ASTRAZENECA RECEIVES FDA APPROVAL TO MARKET ATACAND HCT™

The combination of candesartan cilexetil-hydrochlorothiazide has been evaluated in 12 controlled clinical trials involving approximately 4,600 hypertensive patients. Overall, Atacand HCT was well tolerated, maintaining a blood pressure lowering effect over a full 24-hour period.

Despite the availability of numerous antihypertensive medications, controlling blood pressure in the hypertensive population remains a problem. Recent U. S. public health surveys suggest that only one in five people with hypertension have their blood pressure adequately controlled. To help improve this situation, physicians are turning to fixed-dose combination antihypertensives when desired blood pressure targets are not achieved on monotherapy. Atacand HCT offers dosing flexibility and effective blood pressure control for patients uncontrolled on a single agent.

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of $15 billion and leading positions in sales of gastrointestinal, oncology, anesthesia including pain management, cardiovascular, central nervous system (CNS) and respiratory products.

Further enquires to: